Method for upregulating antigen expression
AssigneeNordic Nanovector AS
InventorsRoy H. Larsen, Ada Repetto-Llamazares
Life of this patent
Estimating the term…
Abstract
The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
Claims15
A method of using a radioimmunoconjugate to upregulate expression of CD20 on the surface of B-cell cancer cells in a subject comprising:
- administering to said subject having B cell cancer cells, a radioimmunoconjugate comprising:
- a monoclonal antibody specific for CD37,
- an optional linker, and
- a radionuclide, wherein
- after administration of radioimmunoconjugate to said subject, said subject is administered an anti-CD20 antibody therapy in a single administration or in a repeated administration pattern.
2-20. (canceled)
A method of treatment of a of a B-cell malignancy selected from the group consisting of non-Hodgkin lymphoma, acute Lymphoblastic Leukemia, and chronic lymphocytic leukemia, comprising:
- administration of radioimmunoconjugate comprising,
- a monoclonal antibody targeting CD37,
- an optional linker,
- a radionuclide, and
- administration of:
- an anti-CD20 antibody, wherein
- the radioimmunoconjugate upregulates antigen expression of an antigen expressed on the surface of B-cell cancer cells, the upregulated antigen is CD20, the upregulation is followed by anti-CD20 antibody therapy in a single administration or in a repeated administration pattern, and the administration of anti-CD20 antibody is after administration of radioimmunoconjugate.
Dependencies are inferred from the claim text.